FDA
-
-
-
-
-
-
-
Axsome Therapeutics presents sleep disorder data at SLEEP 2026 conference
-
-
-
-
-
-
-
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
-
-
-
-
-
-
-
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
-
-
-
-
-
-
-
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
-
-
-
-
-
-
-
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
-
-
-
-
-
-
-
Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'
-
325,416 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

